Dixie‐Lee Esseltine
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Peptidase Inhibition and Analysis
Most-Cited Works
- → Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study(2011)912 cited
- → Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma(2010)858 cited
- → A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma(2004)740 cited
- → Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial(2007)510 cited
- → Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib(2006)418 cited
- → Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study(2006)388 cited
- → PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma(2005)319 cited
- → Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma(2012)265 cited
- → Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials(2013)250 cited
- → A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma(2014)183 cited